News und Analysen

0

AEVIS VICTORIA SA (AEVS.SW) – MRH Switzerland setzt die positive Dynamik im ersten Quartal 2025 fort, angetrieben durch die operative Spitzenleistung seiner Flaggschiffbetriebe

0

Olympus Appoints New CEO

eqs_en

0

EQS-News: Eckert & Ziegler unterzeichnet Herstellungsvereinbarung mit Pentixapharm für Yttrium-90-basiertes PentixaTher

0

Thermo Fisher Stock: Q1 Beat Overshadowed by Outlook Cut

Thermo Fisher Scientific posted strong first-quarter 2025 results, exceeding analyst expectations with earnings per share of $5.15 against predicted $5.10, and revenue of $10.36 billion versus

0

EQS-Adhoc: STRATEC BERICHTET VORLÄUFIGE GESCHÄFTSZAHLEN FÜR 2024, GIBT AUSBLICK FÜR 2025 UND VERSCHIEBT GESCHÄFTSBERICHT 2024

0

3 Stocks to Buy Now for Tariff Immunity

There’s a new commodity in the financial markets today, and that’s any stock (or business, for that matter) that carries a certain level of immunity to the recent trade tariffs rolled out by

0

EQS-HV: Gerresheimer AG: Bekanntmachung der Einberufung zur Hauptversammlung am 05.06.2025 in Düsseldorf mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

0

Medtronic: A Dividend Aristocrat With Stability and Innovation

[content-module:CompanyOverview|NYSE:MDT]

Investors increasingly seek stable and resilient investments in today's volatile and economically uncertain market. Consequently, it is crucial to

0

UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels

[content-module:CompanyOverview|NYSE:UNH]

UnitedHealth Group Inc. (NYSE: UNH) is a bellwether for the health insurance industry. The company symbolized the flaws in managed care organizations

0

Unitedhealth Stock: Dramatic 20% Plunge Shocks Market

UnitedHealth Group shares experienced a catastrophic drop on Thursday, plummeting by over 20% following disappointing first-quarter results. The healthcare giant saw its stock trading as low as

0

Sonova schliesst Aktienrückkauf 2022-25 ab

0

EQS-Adhoc: Maternus-Kliniken AG: Verspätung der Veröffentlichung des Jahres- und Konzernabschlusses für das Jahr 2024, Darlehensverlängerung

0

Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?

Johnson & Johnson (NYSE: JNJ) delivered a solid earnings report on April 15.

[content-module:CompanyOverview|NYSE:JNJ]

On the one hand, the company beat on the top and bottom lines and offered

0

LumenHaus SunSaver gewinnt den Red Dot Design Award 2025

DÜSSELDORF, Deutschland, April 16, 2025 (GLOBE NEWSWIRE) -- Der renommierte Red Dot Design Award 2025 geht an den SunSaver All-in-One Stromspeicher von LumenHaus! Diese Auszeichnung unterstreicht

GlobeNewswire

0

Sartorius Stock: Q1 Results Drive Strong Market Rally

Sartorius, the life science company, impressed investors with robust first-quarter 2025 performance, sending shares notably higher on Wednesday. Revenue increased by 7.7% to €883 million compared to

0

EQS-News: Starker Jahresauftakt: Sartorius erreicht im ersten Quartal deutlich profitables Wachstum

0

2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs

The medical sector stocks, notably the health insurance carriers, took a major drubbing in 2024 as Medicare Advantage (MA) plans continued to drive higher utilization costs, eating away at

0

Draegerwerk Stock: Q1 EBIT Plunges Despite Order Growth

Draegerwerk's first quarter 2025 results present a mixed picture for investors, with the medical and safety technology specialist reporting dramatically lower earnings despite record-breaking order

0

EQS-Adhoc: Carl Zeiss Meditec erzielt deutliche Gewinnsteigerung im zweiten Quartal 2024/25

0

EQS-Adhoc: Drägerwerk AG & Co. KGaA: Vorläufige Zahlen Q1 2025: EBIT unter Vorjahr – Prognose aufgrund guter Auftragsentwicklung bestätigt

0

5 Winning Plays Outperforming the S&P This Year

While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.

This is a look at five stocks

0

EQS-News: Eckert & Ziegler schlägt Dividende von 0,50 € für das GJ 2024 vor

0

Gerresheimer Stock: Mixed Q1 Results Mask Future Growth

Gerresheimer reported seemingly contradictory first-quarter 2025 results, with revenue increasing by 11.6% to €520.1 million while simultaneously posting a net loss of €18 million. This apparent